Activation of PI3K pathway has been described as a mechanism of resistance to hormone therapy and anti-HER2 therapy in breast cancer [100], clinical trials of combinations of these agents with PI3K inhibitors are currently ongoing. This evidence concerns the gene ERBB2 and breast carcinoma.